Loading data for TRDA — first visit, this takes a few seconds.
Entrada Therapeutics Inc. (TRDA)
NasdaqGM: TRDA
· Real-Time Price · USD
7.45
-0.22 (-2.87%)
At close: Aug 13, 2026, 8:00 PM
Entrada Therapeutics Inc. (TRDA) Stock Price, Analysis & Data
-2.87% (1D)
No data available
| Bid | 5.21 |
| Market Cap | 290.08M |
| Revenue (ttm) | 4.69M |
| Net Income (ttm) | -165.78M |
| Beta | -0.26 |
| EPS (ttm) | -3.85 |
| PE Ratio (ttm) | n/a |
| Forward PE | -2.37 |
| P/B (ttm) | 0.99 |
| P/S (ttm) | 61.90 |
| Earnings Date | Nov 5, 2026 |
| Ask | 8.87 |
| Volume | 236,131 |
| Avg. Volume (20D) | 377,596 |
| Open | 7.74 |
| Previous Close | 7.67 |
| Day's Range | 7.37 - 7.76 |
| 52-Week Range | 5.02 - 16.45 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About TRDA
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retina...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 29, 2021
Employees 152
Stock Exchange NasdaqGM
Ticker Symbol TRDA
Website https://www.entradatx.com
Financial Performance
In 2025, Entrada Therapeutics's revenue was 25.42M, a decrease of -87.94% compared to the previous year's 210.78M. Earnings were -143.75M, a decrease of -319.04%.
Financial StatementsEarnings Surprise
Entrada Therapeutics has released their quarterly earnings on Aug 5, 2026:
Entrada Therapeutics Inc. is scheduled to release its earnings on Nov 5, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2